The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Sales | 2,293,313 |
| Cost of sales (excluding depreciation expense) | 872,400 |
| Research and development expense | 2,072,771 |
| Other research and development expenses | 5,504,933 |
| Total research and development expense | 7,577,704 |
| Sales and marketing expense | 4,443,807 |
| General and administrative expense | 6,646,037 |
| Depreciation and amortization expense | 342,034 |
| Total operating expenses | 19,009,582 |
| Total other expense, net | -1,037,921 |
| Loss before income taxes | -18,626,590 |
| Income tax expense | 1,297 |
| Net loss | -18,627,887 |
| Depreciation | 295,859 |
| Amortization | 46,175 |
| Other noncash items | -5,724 |
| Change in fair value of conversion option liability | -503,000 |
| Change in fair value of warrants liabilities | -731,000 |
| Amortization of right-of-use assets | 508,422 |
| Loss on fixed asset dispositions | -62,650 |
| Share-based compensation expense | 790,145 |
| Amortization of debt issuance costs and discount | 1,387,050 |
| Accretion of paid-in-kind interest | 132,140 |
| Accounts receivable | 128,227 |
| Inventory | 2,693,926 |
| Prepaid and other assets | -496,902 |
| Accounts payable | 334,829 |
| Accrued expenses | 474,724 |
| Lease liabilities | -517,967 |
| Other liabilities | -23,178 |
| Net cash used in operating activities | -18,690,565 |
| Acquisition of patents | 105,091 |
| Purchases of property and equipment | 525,007 |
| Net cash used in investing activities | -630,098 |
| Proceeds from the issuance of common stock-Warrants Eight | 4,510,001 |
| Issuance costs-Warrants Eight | 804,940 |
| Proceeds from the issuance of common stock-Warrants Nine | 7,998,826 |
| Issuance costs-Warrants Nine | 930,132 |
| Proceeds from exercise of pre-funded warrants | 500 |
| Proceeds from exercise of common warrants | 3,318,879 |
| Proceeds from november 2025 convertible notes | 12,000,000 |
| Issuance costs for november 2025 convertible notes | 718,528 |
| Proceeds from common stock issued through espp | 90,332 |
| Proceeds from at-the-market sales of common stock | 7,013,162 |
| Issuance costs for at-the-market sales of common stock | 210,395 |
| Repayment of november 2023 convertible notes, including related parties | 6,765,000 |
| Repayment of note payable | 367,450 |
| Net cash provided by financing activities | 25,135,255 |
| Net change in cash and cash equivalents | 5,814,592 |
| Beginning of period | 3,451,761 |
| End of period | 9,266,353 |
FEMASYS INC (FEMY)
FEMASYS INC (FEMY)